PDF(1022 KB)
Clinical features and prognosis of malignancy-associated hemophagocytic lymphohistiocytosis in children: a clinical analysis of 24 cases
ZHANG Wan-Yan, ZHANG Yuan, DONG Nan-Nan, WANG Ying-Chao, SHENG Guang-Yao, XU Xue-Ju, LIU Yu-Feng
Chinese Journal of Contemporary Pediatrics ›› 2018, Vol. 20 ›› Issue (4) : 295-297.
PDF(1022 KB)
PDF(1022 KB)
Clinical features and prognosis of malignancy-associated hemophagocytic lymphohistiocytosis in children: a clinical analysis of 24 cases
Objective To investigate the clinical features and prognosis of malignancy-associated hemophagocytic lymphohistiocytosis (MAHS) in children. Methods A retrospective analysis was performed for the primary diseases, clinical features, and prognosis of 24 children with MAHS. Results Among the 24 children, 11 (46%) had MAHS induced by tumor and 13 (54%) had chemotherapy-associated MAHS. As for primary diseases, 17 children had acute leukemia, 6 had lymphoma, and 1 had neuroblastoma. The most common clinical manifestations were pyrexia, respiratory symptoms, and hepatosplenomegaly. The most common laboratory abnormalities were hemocytopenia, elevated serum ferritin, and elevated lactate dehydrogenase. Of the 24 children, 22 were treated according to the HLH-2004 protocol and 2 gave up treatment; 18 children died, 1 was lost to follow-up, and 5 survived. The survival time ranged from 3 days to 2 years and 4 months (median 28 days). Conclusions Children with MAHS have various clinical features and extremely poor treatment outcomes.
Malignancy-associated hemophagocytic lymphohistiocytosis / Acute leukemia / Lymphoma / Child
[1] Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH):A heterogeneous spectrum of cytokine-driven immune disorders[J]. Cytokine Growth Factor Rev, 2015, 26(3):263-280.
[2] Lehmberg K, Sprekels B, Nichols KE, et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents[J]. Br J Haematol, 2015, 170(4):539-549.
[3] Henter JI, Horne AC, Aricó M, et al. HLH-2004:Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48(2):124-131.
[4] 中华医学会儿科学分会血液学组《中华儿科杂志》编辑委员会. 儿童急性淋巴细胞白血病诊疗建议(第四次修订)[J].中华儿科杂志, 2014, 52(9):641-644.
[5] 中华医学会儿科学分会血液学组《中华儿科杂志》编辑委员会. 儿童急性髓细胞白血病诊疗建议[J]. 中华儿科杂志, 2006, 44(11):877-878.
[6] Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, et al. Adult haemophagocytic symdrome[J]. Lancet, 2014, 383(9927):1503-1516.
[7] Lehmberg K, Nichols KE, Henter JI, et al. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies[J]. Haematologica, 2015, 100(8):997-1004.
[8] 王滕滕, 袁田, 张翼骛. EB病毒与其相关淋巴瘤的研究进展[J]. 中国实验血液学杂志, 2014, 22(6):1775-1779.
[9] Chia J, Yeo KP, Whisstock JC, et al. Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer[J]. Proc Natl Acad Sci U S A, 2009, 106(24):9809-9814.
[10] Clementi R, Locatelli F, Dupré L, et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene[J]. Blood, 2005, 105(11):4424-4428.
[11] Marsh RA, Madden L, Kitchen BJ. XIAP deficiency:a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease[J]. Blood, 2010, 116(7):1079-1082.
[12] 周玉兰, 张荣艳, 李菲. 恶性肿瘤相关噬血细胞综合征的研究新进展[J]. 中国肿瘤临床, 2016, 43(21):958-961.
